Test ID PCDSO Pain Clinic Drug Screen, Urine
Useful For
Detecting drug abuse involving amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, methadone, opiates, phencyclidine, and tetrahydrocannabinol
Detection and identification of prescription or over-the-counter drugs frequently found in drug overdose or used with a suicidal intent
This test is intended to be used in a setting where the identification of the drug is required.
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
CDAU7 | Confirmed Drug Abuse Panel 9, U | Yes | Yes |
OXYSU | Oxycodone Screen, U | Yes | Yes |
PDSU | Drug Screen, Prescription/OTC, U | Yes | Yes |
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
AMPHU | Amphetamines Confirmation, U | Yes | No |
COKEU | Cocaine and metabolite Conf, U | Yes | No |
BENZU | Benzodiazepines Confirmation, U | Yes | No |
BARBU | Barbiturates Confirmation, U | Yes | No |
MTDNU | Methadone Confirmation, U | Yes | No |
PCPU | Phencyclidine Confirmation, U | Yes | No |
THCU | Carboxy-THC Confirmation, U | Yes | No |
ETOH | Ethanol, U | No | No |
OPATU | Opiate Confirmation, U | Yes | No |
OXYCU | Oxycodone w/metabolite Conf, U | Yes | No |
Testing Algorithm
Testing begins with screening tests for alcohol and drugs of abuse. Positives are confirmed and quantitated by definitive methods (gas chromatography-flame ionization detector for ethanol; gas chromatography-mass spectrometry for barbiturates, benzodiazepines, cocaine and metabolites, methadone, phencyclidine, and tetrahydrocannabinol metabolite; liquid chromatography-tandem mass spectrometry for amphetamines and opiates) at an additional charge. If only oxycodone screens positive, only confirmation of oxycodone w/metabolite will be performed. Any other opiate- positive screen will result in the full opiate confirmation being performed.
The drug screen, prescription/OTC will be performed by gas chromatography-mass spectrometry. Qualitative results will be reported.
Method Name
CDAU7, OXYSU: Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay
PDSU: Gas Chromatography-Mass Spectrometry (GC-MS)
ETOH: Gas Chromatography-Flame Ionization Detector (GC-FID) (if appropriate)
Reporting Name
Pain Clinic Drug Screen, USpecimen Type
UrineCollection Container/Tube: Plastic urine container
Submission Container/Tube: Plastic, 60-mL urine bottle
Specimen Volume: 30 mL
Collection Instructions:
1. Collect a random urine specimen.
2. Submit 30 mL in 1 plastic bottle.
3. No preservative.
Additional Information:
1. No specimen substitutions.
2. No STATS are accepted for this procedure.
3. For situations where chain of custody is required, a Chain-of-Custody Kit (T282) is available. For chain-of-custody testing, order PDSOX / Pain Clinic Drug Screen, Chain of Custody, Urine.
4. Additional drug panels and specific requests are available. Call Mayo Medical Laboratories at 800-533-1710 or 507-266-5700.
5. If urine creatinine is required or adulteration of the sample is suspected, the following test should be requested, ADULT / Adulterants Survey, Urine. For additional information, please refer to ADULT / Adulterants Survey, Urine.
6. Submitting less than 30 mL will compromise our ability to perform all necessary testing.
Forms: Chain-of-Custody Request Form is included in the Chain-of-Custody Kit (T282). A copy of this form is also available at http://www.mayomedicallaboratories.com/it-mmfiles/chain-of-custody-request-form.pdf.
Specimen Minimum Volume
25 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Urine | Refrigerated (preferred) | 14 days |
Frozen | 14 days | |
Ambient | 72 hours |
Clinical Information
This panel was designed to screen for and confirm by gas chromatography-mass spectrometry (GC-MS) or gas chromatography-flame ionization detection (GC-FID) the following drugs:
-Barbiturates
-Benzodiazepines
-Cocaine
-Ethanol
-Methadone
-Phencyclidine
-Tetrahydrocannabinol
Confirmation by liquid chromatograph-tandem mass spectrometry (LC-MS/MS) is completed for all opiates and amphetamines.
This panel uses the screening technique which involves immunoassay testing for drugs by class. All positive screening results are confirmed by GC-MS, GC-FID, or LC-MS/MS, and quantitated, before a positive result is reported.
The panel includes PDSU / Drug Screen, Prescription/OTC, Urine, which looks for a broad spectrum of prescription and over-the-counter drugs. It is designed to detect drugs that have toxic effects, as well as known antidotes or active therapies that a clinician can initiate to treat the toxic effect. The test is intended to help physicians manage an apparent overdose or intoxicated patient, to determine if a specific set of symptoms might be due to the presence of drugs, or to evaluate a patient who might be abusing these drugs intermittently. The test is not designed to screen for intermittent use of illicit drugs.
Reference Values
Negative
Screening cutoff concentrations:
Amphetamines: 500 ng/mL
Barbiturates: 200 ng/mL
Benzodiazepines: 100 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Ethanol: 10 mg/dL
Methadone metabolite: 300 ng/mL
Opiates: 300 ng/mL
Phencyclidine: 25 ng/mL
Tetrahydrocannabinol carboxylic acid: 50 ng/mL
This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.
Cautions
Not intended for use in employment-related testing.
For situations where chain of custody is required, a Chain-of-Custody Kit (Supply T282) is available. See PDSOX / Pain Clinic Drug Screen, Chain-of-Custody, Urine.
Day(s) Performed
Monday through Sunday
Report Available
2 daysPerforming Laboratory

CPT Code Information
See individual profile tests
G0479 (if appropriate)